October 19, 2020
A key health ministry panel will review whether to recommend approval for OrphanPacific’s sakigake -designated hereditary angioedema (HAE) treatment berotralstat and AstraZeneca’s chronic lymphocytic leukemia (CLL) drug acalabrutinib at its meeting on October 30. The two drugs are the only...read more